Patents Assigned to Advanced Innovation Development Co. Ltd.
  • HEPATIC FIBROSIS-INHIBITING AGENT AND BROWN FAT CELL-ACTIVATING AGENT CONTAINING TAXIFOLIN
    Publication number: 20220265603
    Abstract: The present invention aims to provide a novel liver fibrosis inhibiting agent or brown adipocyte activating agent, and a prophylactic and/or therapeutic agent for nonalcoholic steatohepatitis which contains the inhibiting agent or activating agent as an active ingredient. The present invention relates to a liver fibrosis inhibiting agent and a brown adipocyte activating agent, each containing taxifolin as an active ingredient, and a prophylactic and/or therapeutic agent for nonalcoholic steatohepatitis, containing taxifolin as an active ingredient.
    Type: Application
    Filed: June 24, 2020
    Publication date: August 25, 2022
    Applicants: NATIONAL HOSPITAL ORGANIZATION, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, Advanced Innovation Development Co., Ltd., FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE
    Inventors: Noriko ASAHARA, Takayuki INOUE, Masashi TANAKA, Masafumi IHARA, Satoshi SAITO
  • Immune adjuvant for cancer
    Patent number: 11065331
    Abstract: The present invention relates to a medicament for treating cancer or infectious disease, the medicament comprising an immune checkpoint blockade and an adjuvant composition. More specifically, the present invention relates to a medicament for cancer or infectious diseases, wherein an anti-PD-1 antibody or an anti-PD-L1 antibody is used in combination with a nucleic acid adjuvant composed of a double-stranded RNA and a single-stranded ODN.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: July 20, 2021
    Assignee: Advanced Innovation Development Co. Ltd.
    Inventors: Tsukasa Seya, Misako Matsumoto
  • IMMUNE ADJUVANT FOR CANCER
    Publication number: 20190160168
    Abstract: The present invention relates to a medicament for treating cancer or infectious disease, the medicament comprising an immune checkpoint blockade and an adjuvant composition. More specifically, the present invention relates to a medicament for cancer or infectious diseases, wherein an anti-PD-1 antibody or an anti-PD-L1 antibody is used in combination with a nucleic acid adjuvant composed of a double-stranded RNA and a single-stranded ODN.
    Type: Application
    Filed: July 26, 2017
    Publication date: May 30, 2019
    Applicant: Advanced Innovation Development Co. Ltd.
    Inventors: Tsukasa SEYA, Misako MATSUMOTO